|
1
|
Yang TM: Clinical pathological features
and survival rate of 116 cases of colorectal cancer. Chin J Med
Guide. 16:602–603. 2014.
|
|
2
|
Zhao S and Xue B: Clinical and
pathological features of rectal cancer in young patients. Mod
Oncol. 21:1296–1298. 2013.
|
|
3
|
Zhang C, Wang Q-T, Liu H, Zhang ZZ and
Huang WL: Advancement and prospects of tumor gene therapy. Chin J
Cancer. 30:182–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hou L-N, He X-H and Zhang Z-X: The present
situation and outlook of the treatment of tumor with cytokine gene.
J Clin Exp Med. 7:145–147. 2008.
|
|
5
|
Sung SY, Hsieh CL, Wu D, Chung LW and
Johnstone PA: Tumor microenvironment promotes cancer progression,
metastasis, and therapeutic resistance. Curr Probl Cancer.
31:36–100. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nelson D, Fisher S and Robinson B: The
‘Trojan Horse’ approach to tumor immunotherapy: Targeting the tumor
microenvironment. J Immunol Res. 2014:7890692014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Egeblad M, Nakasone ES and Werb Z: Tumors
as organs: Complex tissues that interface with the entire organism.
Dev Cell. 18:884–901. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jie L, Zhou X-H, Qian S, et al: The
function of IL-17 family and their roles in related diseases. Curr
Immunol. 34:262–265. 2014.
|
|
9
|
Korn T, Bettelli E, Oukka M and Kuchroo
VK: IL-17 and Th17 Cells. Annu Rev Immunol. 27:485–517. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fossiez F, Djossou O, Chomarat P,
Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E,
Saeland S, et al: T cell interleukin-17 induces stromal cells to
produce proinflammatory and hematopoietic cytokines. J Exp Med.
183:2593–2603. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wakita D, Sumida K, Iwakura Y, Nishikawa
H, Ohkuri T, Chamoto K, Kitamura H and Nishimura T:
Tumor-infiltrating IL-17-producing gammadelta T cells support the
progression of tumor by promoting angiogenesis. Eur J Immunol.
40:1927–1937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He D, Li H, Yusuf N, Elmets CA, Li J,
Mountz JD and Xu H: IL-17 promotes tumor development through the
induction of tumor promoting microenvironments at tumor sites and
myeloid-derived suppressor cells. J Immunol. 184:2281–2288. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dhodapkar KM, Barbuto S, Matthews P,
Kukreja A, Mazumder A, Vesole D, Jagannath S and Dhodapkar MV:
Dendritic cells mediate the induction of polyfunctional human
IL17-producing cells (Th17-1 cells) enriched in the bone marrow of
patients with myeloma. Blood. 112:2878–2885. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Yi T, Kortylewski M, Pardoll DM,
Zeng D and Yu H: IL-17 can promote tumor growth through an
IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirahara N, Nio Y, Sasaki S, Minari Y,
Takamura M, Iguchi C, Dong M, Yamasawa K and Tamura K: Inoculation
of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells
induces T cell-dependent tumor-specific immunity in mice. Oncology.
61:79–89. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Benchetrit F, Ciree A, Vives V, Warnier G,
Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH and
Tartour E: Interleukin-17 inhibits tumor cell growth by means of a
T-cell-dependent mechanism. Blood. 99:2114–2121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirahara N, Nio Y, Sasaki S, Takamura M,
Iguchi C, Dong M, Yamasawa K, Itakura M and Tamura K: Reduced
invasiveness and metastasis of Chinese hamster ovary cells
transfected with human interleukin-17 gene. Anticancer Res 20 (5A).
3137–3142. 2000.
|
|
18
|
Martin-Orozco N, Muranski P, Chung Y, Yang
XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW and Dong C: T
helper 17 cells promote cytotoxic T cell activation in tumor
immunity. Immunity. 31:787–798. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: Malignant B cells skew the balance of regulatory T
cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res.
69:5522–5530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Horlock C, Stott B, Dyson PJ, Morishita M,
Coombes RC, Savage P and Stebbing J: The effects of trastuzumab on
the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with
breast cancer. Br J Cancer. 100:1061–1067. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Muranski P, Boni A, Antony PA, Cassard L,
Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K,
et al: Tumor-specific Th17-polarized cells eradicate large
established melanoma. Blood. 112:362–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sfanos KS, Bruno TC, Maris CH, Xu L,
Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB and Drake CG:
Phenotypic analysis of prostate-infiltrating lymphocytes reveals
TH17 and Treg skewing. Clin Cancer Res. 14:3254–3261. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dougan M and Dranoff G: Inciting
inflammation: The RAGE about tumor promotion. J Exp Med.
205:267–270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kryczek I, Wei S, Szeliga W, Vatan L and
Zou W: Endogenous IL-17 contributes to reduced tumor growth and
metastasis. Blood. 114:357–359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Radosavljevic G, Ljujic B, Jovanovic I,
Srzentic Z, Pavlovic S, Zdravkovic N, Milovanovic M, Bankovic D,
Knezevic M, Acimovic LJ, et al: Interleukin-17 may be a valuable
serum tumor marker in patients with colorectal carcinoma.
Neoplasma. 57:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang J-J and Zheng W-M: The relationship
of IL-13 and its receptor to malignant tumor. Foreign Med Sci Oncol
Sect. 32:736–739. 2005.
|
|
27
|
Terabe M, Park JM and Berzofsky JA: Role
of IL-13 in regulation of anti-tumor immunity and tumor growth.
Cancer Immunol Immunother. 53:79–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
